001     289122
005     20250825122416.0
024 7 _ |a 10.1016/j.critrevonc.2024.104331
|2 doi
024 7 _ |a pmid:38521284
|2 pmid
024 7 _ |a 0737-9587
|2 ISSN
024 7 _ |a 1040-8428
|2 ISSN
024 7 _ |a 1879-0461
|2 ISSN
024 7 _ |a altmetric:161149955
|2 altmetric
037 _ _ |a DKFZ-2024-00589
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Helderman, Noah C
|b 0
245 _ _ |a Emerge of colorectal cancer in Lynch syndrome despite colonoscopy surveillance: A challenge of hide and seek.
260 _ _ |a Amsterdam [u.a.]
|c 2024
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1712309409_10719
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Even with colonoscopy surveillance, Lynch syndromes (LS) carriers still develop colorectal cancer (CRC). The cumulative incidence of CRCs under colonoscopy surveillance varies depending on the affected mismatch repair (MMR) gene. However, the precise mechanisms driving these epidemiological patterns remain incompletely understood. In recent years, several potential mechanisms explaining the occurrence of CRCs during colonoscopy surveillance have been proposed in individuals with and without LS. These encompass biological factors like concealed/accelerated carcinogenesis through a bypassed adenoma stage and accelerated progression from adenomas. Alongside these, various colonoscopy-related factors may contribute to formation of CRCs under colonoscopy surveillance, like missed yet detectable (pre)cancerous lesions, detected yet incompletely removed (pre)cancerous lesions, and colonoscopy-induced carcinogenesis due to tumor cell reimplantation. In this comprehensive literature update, we reviewed these potential factors and evaluated their relevance to each MMR group in an attempt to raise further awareness and stimulate research regarding this conflicting phenomenon.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Colonoscopy surveillance
|2 Other
650 _ 7 |a Colorectal cancer
|2 Other
650 _ 7 |a Incident colorectal cancer
|2 Other
650 _ 7 |a Lynch syndrome
|2 Other
650 _ 7 |a Mismatch repair
|2 Other
650 _ 7 |a Post-colonoscopy colorectal cancer
|2 Other
700 1 _ |a van Leerdam, Monique E
|b 1
700 1 _ |a Kloor, Matthias
|0 P:(DE-He78)028ee60cca729028708496826f077b58
|b 2
|u dkfz
700 1 _ |a Ahadova, Aysel
|0 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000
|b 3
|u dkfz
700 1 _ |a Nielsen, Maartje
|b 4
773 _ _ |a 10.1016/j.critrevonc.2024.104331
|g Vol. 197, p. 104331 -
|0 PERI:(DE-600)2025731-4
|p 104331
|t Critical reviews in oncology, hematology
|v 197
|y 2024
|x 0737-9587
856 4 _ |u https://inrepo02.dkfz.de/record/289122/files/1-s2.0-S104084282400074X-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289122/files/1-s2.0-S104084282400074X-main.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:289122
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)028ee60cca729028708496826f077b58
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CRIT REV ONCOL HEMAT : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CRIT REV ONCOL HEMAT : 2022
|d 2023-10-24
920 1 _ |0 I:(DE-He78)F210-20160331
|k F210
|l KKE Angewandte Tumorbiologie
|x 0
920 1 _ |0 I:(DE-He78)D470-20160331
|k D470
|l KKE Angewandte Tumorbiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F210-20160331
980 _ _ |a I:(DE-He78)D470-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21